Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation

Immunoteràpia del càncer; Resistència terapèutica del càncer

Detalhes bibliográficos
Autores: Román Alonso, Macarena, Luque García, Antonio, Fajardo, Carlos Alberto, Gros Vidal, Alena, Arribas López, Joaquin Vicente, Arenas Lahuerta, Enrique Javier, Martínez-Sabadell, Alex, Rius Ruiz, Irene, Escorihuela Baez, Marta
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/6893
Acesso em linha:https://hdl.handle.net/11351/6893
Access Level:acceso abierto
Palavra-chave:Càncer - Immunoteràpia
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/immunology
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/inmunología
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
id ES_eeefcd63e2d4abafb186ffe6b5de35a5
oai_identifier_str oai:recercat.cat:11351/6893
network_acronym_str ES
network_name_str España
repository_id_str
spelling Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulationRomán Alonso, MacarenaLuque García, AntonioFajardo, Carlos AlbertoGros Vidal, AlenaArribas López, Joaquin VicenteArenas Lahuerta, Enrique JavierMartínez-Sabadell, AlexRius Ruiz, IreneEscorihuela Baez, MartaCàncer - ImmunoteràpiaResistència als medicamentsDISEASES::NeoplasmsOther subheadings::Other subheadings::Other subheadings::/immunologyPHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, NeoplasmENFERMEDADES::neoplasiasOtros calificadores::Otros calificadores::Otros calificadores::/inmunologíaFENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicosImmunoteràpia del càncer; Resistència terapèutica del càncerInmunoterapia contra el cáncer; Resistencia terapéutica del cáncerCancer immunotherapy; Cancer therapeutic resistanceImmunotherapy has raised high expectations in the treatment of virtually every cancer. Many current efforts are focused on ensuring the efficient delivery of active cytotoxic cells to tumors. It is assumed that, once these active cytotoxic cells are correctly engaged to cancer cells, they will unfailingly eliminate the latter, provided that inhibitory factors are in check. T cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs) offer an opportunity to test this assumption. Using TCB and CARs directed against HER2, here we show that disruption of interferon-gamma signaling confers resistance to killing by active T lymphocytes. The kinase JAK2, which transduces the signal initiated by interferon-gamma, is a component repeatedly disrupted in several independently generated resistant models. Our results unveil a seemingly widespread strategy used by cancer cells to resist clearance by redirected lymphocytes. In addition, they open the possibility that long-term inhibition of interferon-gamma signaling may impair the elimination phase of immunoediting and, thus, promote tumor progression.Nature ResearchInstitut Català de la Salut[Arenas EJ, Rius Ruiz I] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. [Martínez-Sabadell A, Román Alonso M, Escorihuela M, Luque A] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fajardo CA, Gros A] Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. [Arribas J] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, SpainVall d'Hebron Barcelona Hospital Campus202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/6893Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésNature Communications;12https://doi.org/10.1038/s41467-021-21445-4Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/68932026-05-29T05:05:01Z
dc.title.none.fl_str_mv Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
title Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
spellingShingle Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Román Alonso, Macarena
Càncer - Immunoteràpia
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/immunology
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/inmunología
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
title_short Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
title_full Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
title_fullStr Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
title_full_unstemmed Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
title_sort Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
dc.creator.none.fl_str_mv Román Alonso, Macarena
Luque García, Antonio
Fajardo, Carlos Alberto
Gros Vidal, Alena
Arribas López, Joaquin Vicente
Arenas Lahuerta, Enrique Javier
Martínez-Sabadell, Alex
Rius Ruiz, Irene
Escorihuela Baez, Marta
author Román Alonso, Macarena
author_facet Román Alonso, Macarena
Luque García, Antonio
Fajardo, Carlos Alberto
Gros Vidal, Alena
Arribas López, Joaquin Vicente
Arenas Lahuerta, Enrique Javier
Martínez-Sabadell, Alex
Rius Ruiz, Irene
Escorihuela Baez, Marta
author_role author
author2 Luque García, Antonio
Fajardo, Carlos Alberto
Gros Vidal, Alena
Arribas López, Joaquin Vicente
Arenas Lahuerta, Enrique Javier
Martínez-Sabadell, Alex
Rius Ruiz, Irene
Escorihuela Baez, Marta
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Arenas EJ, Rius Ruiz I] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. [Martínez-Sabadell A, Román Alonso M, Escorihuela M, Luque A] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fajardo CA, Gros A] Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. [Arribas J] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28029, Spain. Tumor Immunology & Immunotherapy Group, VHIO, Barcelona, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona 08003, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Càncer - Immunoteràpia
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/immunology
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/inmunología
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
topic Càncer - Immunoteràpia
Resistència als medicaments
DISEASES::Neoplasms
Other subheadings::Other subheadings::Other subheadings::/immunology
PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm
ENFERMEDADES::neoplasias
Otros calificadores::Otros calificadores::Otros calificadores::/inmunología
FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos
description Immunoteràpia del càncer; Resistència terapèutica del càncer
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/6893
url https://hdl.handle.net/11351/6893
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Nature Communications;12
https://doi.org/10.1038/s41467-021-21445-4
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423792038608896
score 15,81155

Registos relacionados